Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Cocaine Use Disorder

In brief

This is a phase II, randomized, single-blind, placebo-controlled study to examine whether cariprazine (1.5 or 3 mg/d) 1) alters brain and/or behavioral responses to probes of reward and inhibition and 2) decreases cocaine use in individuals with cocaine use disorder. Subjects will be tested as inpatients during fMRI sessions. After the 2-week inpatient/medication induction phase, study medication will continue for 8 outpatient weeks, during which time cocaine use will be tracked. Subjects will be monitored during a 4-wk followup phase thereafter.

Key facts

Study ID
NCT03430544
Run by
Anna Rose Childress, Ph.D.
People needed
14
Starts
2018-04-04
Expected to finish
2020-09-04
Last updated by the study team
2020-09-09

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.